The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.
iShares Genomics Immnlgy & Hlthcr ETF IDNA
Morningstar’s Analysis IDNA
Will IDNA outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Revolution Medicines Inc Ordinary Shares | 5.64 | 7.3 Mil | Healthcare |
Sarepta Therapeutics Inc | 5.28 | 6.9 Mil | Healthcare |
Moderna Inc | 5.15 | 6.7 Mil | Healthcare |
Merck & Co Inc | 4.67 | 6.1 Mil | Healthcare |
GSK PLC | 4.31 | 5.6 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.24 | 5.5 Mil | Healthcare |
Exelixis Inc | 4.04 | 5.3 Mil | Healthcare |
Sanofi SA | 3.89 | 5.1 Mil | Healthcare |
Incyte Corp | 3.64 | 4.7 Mil | Healthcare |
Takeda Pharmaceutical Co Ltd | 3.58 | 4.7 Mil | Healthcare |